Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures

Cytek Biosciences, Inc. (CTKB) has disclosed a new risk, in the Capital Markets category.

The analyst notes that Cytek Biosciences, Inc. faces heightened exposure to shifting tariffs and trade restrictions that could raise component costs and erode its pricing competitiveness globally. Any escalation in U.S.–China tensions, sanctions, or broader protectionist measures could disrupt key suppliers, dampen international demand, and materially pressure its margins and overall financial performance.

The average CTKB stock price target is $6.25, implying 35.57% upside potential.

To learn more about Cytek Biosciences, Inc.’s risk factors, click here.